MCID: SCH003
MIFTS: 43

Schizophreniform Disorder

Categories: Mental diseases

Aliases & Classifications for Schizophreniform Disorder

MalaCards integrated aliases for Schizophreniform Disorder:

Name: Schizophreniform Disorder 12 76 15
Schizophreniform Disorders 55 73
Psychotic Disorders 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11328
ICD10 33 F20.81
ICD9CM 35 295.4
MeSH 44 D011618
NCIt 50 C94376
SNOMED-CT 68 88975006

Summaries for Schizophreniform Disorder

Disease Ontology : 12 A psychotic disorder that involves schizophrenia symptoms over time period of one month.

MalaCards based summary : Schizophreniform Disorder, also known as schizophreniform disorders, is related to schizoaffective disorder and schizophrenia, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Schizophreniform Disorder is PRL (Prolactin), and among its related pathways/superpathways is Signaling by ERBB4. The drugs Dopamine and Sulpiride have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and bone.

Wikipedia : 76 Schizophreniform disorder is a mental disorder diagnosed when symptoms of schizophrenia are present for... more...

Related Diseases for Schizophreniform Disorder

Diseases related to Schizophreniform Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 schizoaffective disorder 31.8 COMT DRD2 PRL
2 schizophrenia 30.5 COMT DRD2 NRG1 PRL
3 traumatic brain injury 30.1 COMT DRD2
4 brain injury 30.1 COMT DRD2
5 substance abuse 30.0 COMT DRD2 PRL
6 hyperprolactinemia 29.9 DRD2 PRL
7 post-traumatic stress disorder 29.8 COMT DRD2
8 disease of mental health 29.7 COMT DRD2 NRG1 SLC27A5
9 obsessive-compulsive disorder 29.6 COMT DRD2 PRL
10 pituitary adenoma, prolactin-secreting 29.6 DRD2 PRL
11 major depressive disorder 29.6 COMT DRD2 PRL
12 alcohol abuse 29.6 DRD2 PRL
13 personality disorder 29.6 COMT DRD2 PRL
14 mood disorder 29.6 COMT DRD2
15 cannabis dependence 29.5 COMT NRG1
16 alexithymia 29.5 COMT DRD2
17 bipolar i disorder 29.5 COMT NRG1
18 psychotic disorder 29.3 COMT DRD2 NRG1 PRL
19 bipolar disorder 29.3 COMT DRD2 NRG1 PRL
20 narcolepsy 29.1 COMT DRD2
21 drug psychosis 11.2
22 mental retardation, x-linked, syndromic 13 10.9
23 schizophrenia 4 10.9
24 schizophrenia 2 10.9
25 schizophrenia 9 10.9
26 schizophrenia 15 10.9
27 chromosome 2p16.3 deletion syndrome 10.9
28 schizophrenia 18 10.9
29 schizophrenia 19 10.9
30 epilepsy 10.2
31 galactorrhea 10.1 DRD2 PRL
32 prolactin producing pituitary tumor 10.1 DRD2 PRL
33 social phobia 10.1 DRD2 PRL
34 peripartum cardiomyopathy 10.1 DRD2 PRL
35 functioning pituitary adenoma 10.1 DRD2 PRL
36 depression 10.1
37 migraine without aura 10.1 DRD2 PRL
38 cocaine abuse 10.1 DRD2 PRL
39 mammographic density 10.0 COMT PRL
40 autism 10.0
41 cognitive function 1, social 10.0
42 coronary heart disease 1 10.0
43 heart disease 10.0
44 encephalopathy 10.0
45 fibromyalgia 10.0 COMT PRL
46 postpartum depression 9.9 COMT PRL
47 polysubstance abuse 9.9 COMT DRD2
48 tardive dyskinesia 9.9 COMT DRD2
49 anxiety 9.9
50 borderline personality disorder 9.9

Comorbidity relations with Schizophreniform Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 118)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Adjustment Disorder
Age-Related Hearing Loss Alcohol Abuse
Alzheimer Disease Amnestic Disorder
Antisocial Personality Disorder Anxiety
Aortic Valve Disease 1 Atypical Depressive Disorder
Bacteremia 2 Bipolar Disorder
Blepharitis Borderline Personality Disorder
Brain Cancer Bronchitis
Bronchopneumonia Bullous Pemphigoid
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Ulcer of Skin
Communicating Hydrocephalus Conduct Disorder
Conjunctivitis Conversion Disorder
Cyclothymic Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dermatomycosis Diabetes Mellitus, Noninsulin-Dependent
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Erythematosquamous Dermatosis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Fecal Incontinence
Folic Acid Deficiency Anemia Generalized Anxiety Disorder

Graphical network of the top 20 diseases related to Schizophreniform Disorder:



Diseases related to Schizophreniform Disorder

Symptoms & Phenotypes for Schizophreniform Disorder

UMLS symptoms related to Schizophreniform Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, clouded consciousness, catatonic reaction

Drugs & Therapeutics for Schizophreniform Disorder

Drugs for Schizophreniform Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Sulpiride Approved, Investigational Phase 4,Not Applicable 15676-16-1 5355
3
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
4
Armodafinil Approved, Investigational Phase 4 112111-43-0
5
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
6
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
7
Donepezil Approved Phase 4 120014-06-4 3152
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
13
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
16
Pravastatin Approved Phase 4 81093-37-0 54687
17
Molindone Approved Phase 4 7416-34-4 23897
18
Metformin Approved Phase 4 657-24-9 14219 4091
19
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 sultopride Phase 4,Not Applicable
27 Antidepressive Agents Phase 4,Not Applicable
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Wakefulness-Promoting Agents Phase 4
33 Cytochrome P-450 CYP3A Inducers Phase 4
34 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Central Nervous System Stimulants Phase 4,Not Applicable
36 Nootropic Agents Phase 4
37 Cholinergic Agents Phase 4,Not Applicable
38 Cholinesterase Inhibitors Phase 4
39 Antineoplastic Agents, Hormonal Phase 4
40 Hormone Antagonists Phase 4,Phase 3,Phase 2
41 Hormones Phase 4,Phase 3,Phase 2
42 glucocorticoids Phase 4
43 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Prednisolone acetate Phase 4
46 Neuroprotective Agents Phase 4
47 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
2 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
3 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
4 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
5 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
6 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia Completed NCT02137993 Phase 4 A-prexa;Zyprexa
7 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Completed NCT00304655 Phase 4 Aripiprazole
8 Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Completed NCT00485823 Phase 4 Olanzapine Hydrochloride
9 DECIFER: Depression and Citalopram In First Episode Recovery Completed NCT01041274 Phase 4 Citalopram;Placebo
10 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
11 Varenicline Adjunctive Treatment in Schizophrenia Completed NCT00492349 Phase 4 Varenicline;Placebo
12 Optimization of Treatment and Management of Schizophrenia in Europe Completed NCT01248195 Phase 4 Amisulpride open label;6-week amisulpride double blind treatment;6-week olanzapine double blind treatment;12-week clozapine open-label treatment
13 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
14 Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia Completed NCT00103571 Phase 4 Olanzapine;Aripiprazole
15 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia Completed NCT00847600 Phase 4
16 Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia Completed NCT01082588 Phase 4 Pravastatin;Placebo
17 Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
18 Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia Completed NCT00595504 Phase 4 Ramelteon;Placebo
19 Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia Completed NCT00361543 Phase 4 Raloxifene hydrochloride
20 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia Completed NCT00337662 Phase 4 olanzapine;risperidone;risperidone
21 Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia Completed NCT00330551 Phase 4 Oral Risperidone;Risperidone in Long-Acting Injectable Form (Consta)
22 An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications. Completed NCT00391261 Phase 4 Metformin
23 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia Completed NCT00333177 Phase 4 Risperidone, administered orally;Risperidone, administered via injection
24 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis Completed NCT00320671 Phase 4 Aripiprazole;Risperidone
25 Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? Recruiting NCT01481883 Phase 4 Raloxifene Hydrochloride;Placebo
26 Research Into Antipsychotic Discontinuation and Reduction Trial Recruiting NCT03559426 Phase 4 Antipsychotic Reduction;Antipsychotic Maintenance
27 Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia Recruiting NCT01451736 Phase 4 paliperidone palmitate;risperidone
28 Schizophrenic Patients in Integrated Care Terminated NCT00681629 Phase 4 Quetiapine XR
29 Optimizing Response in Psychosis Study Terminated NCT00314327 Phase 4 long-acting injectable risperidone
30 Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia Withdrawn NCT03061136 Phase 4 Clonazepam;Placebo
31 Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia Unknown status NCT01121042 Phase 3 Ondansetron;Placebo
32 Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients Completed NCT00159770 Phase 3 ziprasidone versus olanzapine , risperidone or quetiapine
33 Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study Completed NCT00145444 Phase 3 olanzapine;ziprasidone
34 CAFE Comparison of Atypicals in First Episode of Psychosis Completed NCT00034892 Phase 3 Olanzapine, risperidone
35 Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Completed NCT00419146 Phase 2, Phase 3 Ethyl-eicosapentaenoic acid (EPA);Vitamins E + C
36 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents Completed NCT00421954 Phase 3 Ziprasidone
37 A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis Completed NCT00216580 Phase 3 Risperidone, long-acting injectable
38 Simvastatin Addition for Patients With Recent-onset Schizophrenia Recruiting NCT01999309 Phase 3 Simvastatin;Placebo
39 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Recruiting NCT03187769 Phase 3 ALKS 3831;Olanzapine
40 Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder Recruiting NCT03043820 Phase 3 Raloxifene;Placebo
41 A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Active, not recruiting NCT02431702 Phase 3 Aripiprazole;Haloperidol;Olanzapine;Oral Paliperidone ER;Perphenazine;Quetiapine;Oral Risperidone;Paliperidone Palmitate Injection (PP1M);Paliperidone Palmitate Injection (PP3M)
42 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Enrolling by invitation NCT03201757 Phase 3 ALKS 3831
43 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
44 A Definitive Estrogen Patch Study (ADEPT) Completed NCT00357006 Phase 2 Estradiol;Estradiol
45 Effectiveness of Adherence Therapy for Schizophrenia Completed NCT01780116 Phase 1, Phase 2
46 Clinical Estradiol Trial in Women With Schizophrenia Completed NCT00206570 Phase 2 Estradiol
47 The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study Completed NCT00206557 Phase 2 Raloxifene;Estradiol/dyhydroprogestrone
48 Randomized Double Blind Placebo Control Study in Patients With Schizophrenia Completed NCT01602029 Phase 2 Ondansetron;Simvastatin;Placebo;Odansetron plus simvastatin
49 Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents Completed NCT01731119 Phase 2 Latuda©
50 Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain Completed NCT00709202 Phase 2 Betahistine;Placebo Oral Tablet

Search NIH Clinical Center for Schizophreniform Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: psychotic disorders

Genetic Tests for Schizophreniform Disorder

Anatomical Context for Schizophreniform Disorder

MalaCards organs/tissues related to Schizophreniform Disorder:

41
Testes, Brain, Bone, Liver, Heart, Pituitary, Temporal Lobe

Publications for Schizophreniform Disorder

Articles related to Schizophreniform Disorder:

(show top 50) (show all 96)
# Title Authors Year
1
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. ( 30115598 )
2018
2
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder. ( 28839335 )
2017
3
Hypocalcemia Masquerading as Schizophreniform Disorder. ( 27833232 )
2016
4
White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. ( 26774424 )
2016
5
Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder. ( 21614663 )
2012
6
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. ( 20493229 )
2010
7
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. ( 19154213 )
2009
8
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder. ( 19555799 )
2009
9
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). ( 19369319 )
2009
10
Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. ( 19156152 )
2009
11
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). ( 19819114 )
2009
12
Specific brain structural abnormalities in first-episode schizophrenia. A comparative study with patients with schizophreniform disorder, non-schizophrenic non-affective psychoses and healthy volunteers. ( 19796919 )
2009
13
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. ( 18312044 )
2008
14
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. ( 18280582 )
2008
15
Schizophreniform disorder after heat injury in a military recruit. ( 18621941 )
2008
16
Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. ( 18053652 )
2008
17
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. ( 18374841 )
2008
18
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 17854239 )
2007
19
Predictors of the evolution towards schizophrenia or mood disorder in patients with schizophreniform disorder. ( 17851043 )
2007
20
Chromosomal translocation t(1;4) (p21;p14) indicating possible susceptibility loci for schizophreniform disorder and mental retardation. ( 17827423 )
2007
21
Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. ( 17077440 )
2006
22
Improvement of psychiatric symptoms after electroconvulsive therapy in young adults with intractable first-episode schizophrenia and schizophreniform disorder. ( 17077598 )
2006
23
Supportive psychotherapy for a patient with psychosis: schizophreniform disorder. ( 21103151 )
2006
24
Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. ( 16279874 )
2005
25
Patients with schizophreniform disorder use verbal descriptions for the representation of visual categories. ( 14982130 )
2004
26
Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report. ( 15069468 )
2004
27
A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. ( 15206670 )
2004
28
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. ( 15231551 )
2004
29
Outcome of schizophreniform disorder. ( 12773271 )
2003
30
Persistent early childhood developmental impairment may be associated with later schizophreniform disorder. ( 12588823 )
2003
31
Schizophreniform disorder with cerebrospinal fluid PCR positivity for herpes simplex virus type 1. ( 14530627 )
2003
32
Childhood origins of violent behaviour in adults with schizophreniform disorder. ( 14645023 )
2003
33
Distinguishing between first-admission schizophreniform disorder and schizophrenia. ( 12765743 )
2003
34
Exploration of dimensions of psychopathology in neuroleptic-naA^ve patients with recent-onset schizophrenia/schizophreniform disorder. ( 14572620 )
2003
35
Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. ( 12611829 )
2003
36
A follow-up study of patients with DSM-IV schizophreniform disorder. ( 11873709 )
2002
37
Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. ( 11982449 )
2002
38
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states. ( 12399138 )
2002
39
Treatment of a biracial child with schizophreniform disorder: cultural formulation. ( 10975171 )
2000
40
Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. ( 11074871 )
2000
41
First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. ( 11099883 )
2000
42
Induction of a schizophreniform disorder by a spinal cord stimulator. ( 9989125 )
1999
43
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. ( 10584762 )
1999
44
Schizophreniform disorder: exception proves the rule. ( 10360149 )
1999
45
Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. ( 9734543 )
1998
46
DSM-III-R schizophreniform disorder with good prognostic features: a six-year follow-up. ( 9533972 )
1998
47
Oculo-auriculo-vertebral spectrum disorder (Goldenhar "syndrome") coexisting with schizophreniform disorder. ( 9667580 )
1998
48
Family history of DSM-III-R schizophreniform disorder with good prognostic features. ( 9653543 )
1998
49
Comorbidity of schizophreniform disorder and borderline personality disorder in an 18-year-old black woman. ( 9521370 )
1998
50
The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. ( 9018389 )
1997

Variations for Schizophreniform Disorder

Expression for Schizophreniform Disorder

Search GEO for disease gene expression data for Schizophreniform Disorder.

Pathways for Schizophreniform Disorder

Pathways related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.66 NRG1 PRL

GO Terms for Schizophreniform Disorder

Cellular components related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GABA-ergic synapse GO:0098982 8.96 DRD2 NRG1
2 axon GO:0030424 8.8 COMT DRD2 NRG1

Biological processes related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.43 COMT PRL
2 response to ethanol GO:0045471 9.4 DRD2 PRL
3 female pregnancy GO:0007565 9.37 COMT PRL
4 locomotory behavior GO:0007626 9.32 DRD2 NRG1
5 synapse assembly GO:0007416 9.26 DRD2 NRG1
6 mammary gland development GO:0030879 9.16 NRG1 PRL
7 dopamine metabolic process GO:0042417 8.96 COMT DRD2
8 response to drug GO:0042493 8.92 COMT DRD2 PRL SEMA3C

Molecular functions related to Schizophreniform Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemorepellent activity GO:0045499 8.62 NRG1 SEMA3C

Sources for Schizophreniform Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....